Top 10 Global Pharmaceutical Company Awards $1.3 Million in Studies to eResearchTechnology for Cardiac Safety Monitoring and Inf
March 08 2005 - 8:05AM
PR Newswire (US)
Top 10 Global Pharmaceutical Company Awards $1.3 Million in Studies
to eResearchTechnology for Cardiac Safety Monitoring and
Information Distribution Services Phase III Program Award Leverages
Semi-Automated Readings to Ensure Consistent Cardiac Safety
Monitoring Throughout the Development Process PHILADELPHIA, March 8
/PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT)
(NASDAQ:ERES), a leading provider of centralized
electrocardiographic (ECG) collection and interpretation services,
announced today that it has been awarded more than $1.3 million in
cardiac safety monitoring and services from a top 10 global
pharmaceutical organization for one of its key drug candidates in
late phase clinical trials. The award for the Phase III program is
comprised of a number of studies with an investigator network that
spans three continents. eRT will provide comprehensive support,
including provision of 128 units of digital 12-lead ECG equipment
designed to facilitate collection of cardiac safety data that is
subsequently provided to eRT for analysis. eRT will perform digital
collection, measurement, interpretation, review, and distribution
of cardiac safety data through its EXPeRT(R) workflow enabled data
handling technology, the first solution in production that was
designed explicitly to meet emerging international regulatory
guidance and technical standards. "eRT is pleased to have been
selected for these important studies, which represent our initial
program level award from this leading global drug development
organization," said Scott Grisanti, senior vice president of
business development and chief marketing officer at eRT.
"Increasingly, sponsors are recognizing the scientific and business
synergies that can be realized in partnering with an ECG core
laboratory, such as eRT, that has the capacity, throughput, and
global capabilities to manage multiple simultaneous studies in a
consistent manner." Based in Philadelphia, PA, eResearchTechnology,
Inc. (http://www.ert.com/) is a provider of technology and services
to the pharmaceutical, biotechnology and medical device industries
on a global basis. The company is a market leader in providing
centralized core-diagnostic electrocardiographic (ECG) technology
and services to evaluate cardiac safety in clinical development.
The company is also a leader in providing technology and services
to streamline the clinical trials process by enabling its customers
to automate the collection, analysis, and distribution of clinical
data in all phases of clinical development. Statements included in
this release may constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such statements involve a number of risks and uncertainties such as
competitive factors, technological development, market demand, and
the company's ability to obtain new contracts and accurately
estimate net revenues due to variability in size, scope and
duration of projects, and internal issues in the sponsoring client.
The sponsor may cancel this agreement at its sole discretion. As a
result, actual results may differ materially from any financial
outlooks stated herein. Further information on potential factors
that could affect the company's financial results can be found in
the company's Reports on Forms 10-K and 10-Q filed with the
Securities and Exchange Commission. DATASOURCE:
eResearchTechnology, Inc. CONTACT: Joan Sterlacci,
eResearchTechnology, Inc., +1-908-203-6473; or Matt Hayden, Hayden
Communications, +1-858-704-5065, for eResearchTechnology Web site:
http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about East Resources Acquisition Company (NASDAQ): 0 recent articles
More Eresearch Tech (MM) News Articles